The stock price of Vertex Pharmaceuticals stock has seen a rise of 7.5% over the last month, while it is up 11% over the last ten trading days. The recent rise can be attributed to positive results from a mid-stage study evaluating VX-147 in treating patients with focal segmental glomerulosclerosis.
The stock price of Vertex Pharmaceuticals stock has seen a rise of 7.5% over the last month, while it is up 11% over the last ten trading days. The recent rise can be attributed to positive results from a mid-stage study evaluating VX-147 in treating patients with focal segmental glomerulosclerosis.
Share this Article
Recommended